Abstract 2216P
Background
Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC) is commonly observed in young patients, with a median age at diagnosis in the third decade of life. Further, the risk of recurrence is higher with DSVPTC than with classical papillary thyroid carcinoma (PTC). Therefore, this study aimed to describe the clinicopathological and genetic characteristics of patients of different ages with DSVPTC.
Methods
We retrospectively reviewed 397 patients who underwent thyroidectomy for DSVPTC at the Gangnam Severance Hospital, Yonsei University from January 2005 to December 2017. We selected 41 patients through random sampling by their age group, and examined mutations in 119 genes using next-generation sequencing.
Results
The mean age at diagnosis was 36.7±11.6 years, with the majority of patients (163, 41.1%) in their third decades. DSVPTC was predominant in women (276, 69.5%), compared with men. We observed recurrence in 46 patients (11.6%), with regional nodal recurrence being the most common recurrence site (32 patients, 69.6%). The tumour size increased in younger patients (<20 years: 2.69±1.56, 21–30 years: 1.88±1.30, and 31–40 years: 1.55±0.95), those displaying a plateau in their fourth (1.38±0.85) and fifth (1.29±0.91) decades, and those above 61 years of age (1.63±1.45). The initial presentation of cancer was more aggressive in paediatric patients with a larger size, more common multiplicity, and lateral neck metastasis. V-raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten rat sarcoma virus (KRAS), and telomerase reverse transcriptase (TERT) displayed relatively higher mutations, compared with other genes.
Conclusions
DSVPTC displayed different clinical, pathological, and molecular profiles, compared with papillary thyroid carcinoma. BRAF, KRAS, and TERT were the most important genetic mutations, with differences depending on the age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15